MARKET

XOMA

XOMA

XOMA Royalty Corporation
NASDAQ
29.91
-1.22
-3.92%
After Hours: 29.91 0 0.00% 17:01 12/05 EST
OPEN
30.38
PREV CLOSE
31.13
HIGH
31.16
LOW
29.60
VOLUME
44.54K
TURNOVER
--
52 WEEK HIGH
39.92
52 WEEK LOW
18.35
MARKET CAP
370.38M
P/E (TTM)
40.08
1D
5D
1M
3M
1Y
5Y
1D
*News On Mural Oncology PLC (MURA) Now Under XOMA
Dow Jones · 10h ago
Xoma Completes Acquisition of Mural Oncology
TipRanks · 17h ago
Xoma announces closing of transaction to acquire Mural Oncology
TipRanks · 18h ago
BRIEF-Xoma Royalty Announces Closing Of Transaction To Acquire Mural Oncology PLC
Reuters · 18h ago
*XOMA Royalty Announces Closing Of Transaction To Acquire Mural Oncology Plc >XOMA
Dow Jones · 18h ago
Press Release: XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
Dow Jones · 18h ago
Mural Oncology announces effectiveness of scheme of arrangement
TipRanks · 19h ago
Mural Oncology Acquisition By XOMA Royalty Subsidiary Effective December 5, Under Companies Act Scheme
Benzinga · 19h ago
More
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.

Webull offers XOMA Royalty Corp stock information, including NASDAQ: XOMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XOMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XOMA stock methods without spending real money on the virtual paper trading platform.